Isatuximab with carfilzomib and dexamethasone for multiple myeloma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of drugs (isatuximab, carfilzomib, and dexamethasone) given as shots under the skin for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if this mix works better than previous options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma that has come back or is not responding to treatment.
- You must have tried at least 1 but no more than 3 prior treatments for this disease.
- Your cancer must be measurable, meaning certain levels in your blood or urine are high enough to track.
- You must not be allergic to any of the study drugs or their components.
- You must be willing to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests isatuximab (an anti-cancer antibody) combined with other study medicines in people whose multiple myeloma has come back or not responded. It aims to improve control of the disease after you’ve already had multiple prior treatments.
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
This trial tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) for people newly diagnosed with multiple myeloma who are either unable or choose not to have a stem cell transplant. The goal is to see if this combination can effectively control the disease.
This trial is testing a combination of three drugs (carfilzomib, cyclophosphamide, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to previous treatments, especially if they've already had lenalidomide. The goal is to see if this combination can help control the cancer.
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
This study allows people with multiple myeloma who are already benefiting from the drug isatuximab in an earlier clinical trial to keep receiving it after that trial ends. It is an extension study, meaning you can continue your treatment without interruption.
Hear when a new Plasma Cell Myeloma Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.